Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis

Vaccine

Volumn 29, Issue 44, 2011, Pages 7759-7765

  West, Nicholas P ^a   Thomson, Scott A ^b   Triccas, James A ^c   Medveczky, C Jill ^b   Ramshaw, Ian A ^b   Britton, Warwick J ^a,c  

^a CENTENARY INSTITUTE   (Australia)

^b Australian National University   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Coimmunization; HIV; Savine; Tuberculosis; Vaccine

Indexed keywords

BACTERIAL PROTEIN; CD4 ANTIGEN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VACCINIA VACCINE;

ARTICLE; BACTERIAL IMMUNITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FOWLPOX VIRUS; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 80053587106     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.109     Document Type: Article

References (44)

1. Dye C., Williams B.G. The population dynamics and control of tuberculosis. Science 2010, 328(May (5980)):856-861.
2. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., van Soolingen D., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375(May (9728)):1830-1843.
3. Kaufmann S.H., Hussey G., Lambert P.H. New vaccines for tuberculosis. Lancet 2010, 375(June (9731)):2110-2119.
4. Rosenthal S.R., Loewinsohne, Graham M.L., Liveright D., Thorne G., Johnson V. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics 1961, 28(October):622-641.
5. Hart P.D., Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977, 2(July (6082)):293-295.
6. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346(November (8986)):1339-1345.
7. Lawn S.D., Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009, 4(July (4)):325-333.
8. Mukadi Y.D., Maher D., Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001, 15(January (2)):143-152.
9. Hesseling A.C., Marais B.J., Gie R.P., Schaaf H.S., Fine P.E., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25(January (1)):14-18.
10. Ritz N., Hanekom W.A., Robins-Browne R., Britton W.J., Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008, 32(August (5)):821-841.
11. Harding C.V., Boom W.H. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 2010, 8(April (4)):296-307.
12. Britton W.J., Palendira U. Improving vaccines against tuberculosis. Immunol Cell Biol 2003, 81(February (1)):34-45.
13. Aagaard C., Dietrich J., Doherty M., Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 2009, 87(May-June (4)):279-286.
14. Brookes R.H., Hill P.C., Owiafe P.K., Ibanga H.B., Jeffries D.J., Donkor S.A., et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008, 3(8):e2921.
15. Xing Z., Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006, 86(May-July (3-4)):211-217.
16. Vordermeier H.M., Rhodes S.G., Dean G., Goonetilleke N., Huygen K., Hill A.V., et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 2004, 112(July (3)):461-470.
17. Shanahan E.R., Pinto R., Triccas J.A., Britton W.J., West N.P. Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. Vaccine 2010, 28(February (5)):1341-1346.
18. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999, 67(April (4)):1702-1707.
19. Thomson S.A., Jaramillo A.B., Shoobridge M., Dunstan K.J., Everett B., Ranasinghe C., et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005, 23(September (38)):4647-4657.
20. Lutzky V.P., Corban M., Heslop L., Morrison L.E., Crooks P., Hall D.F., et al. Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 2010, 84(January (1)):407-417.
21. Kelleher A.D., Puls R.L., Bebbington M., Boyle D., Ffrench R., Kent S.J., et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006, 20(January (2)):294-297.
22. West N.P., Wozniak T.M., Valenzuela J., Feng C.G., Sher A., Ribeiro J.M., et al. Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis. Vaccine 2008, 26(July (31)):3853-3859.
23. Ranasinghe C., Turner S.J., McArthur C., Sutherland D.B., Kim J.H., Doherty P.C., et al. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007, 178(February (4)):2370-2379.
24. Brandt L., Oettinger T., Holm A., Andersen A.B., Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 1996, 157(October (8)):3527-3533.
25. Romano M., Denis O., D'Souza S., Wang X.M., Ottenhoff T.H., Brulet J.M., et al. Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of Mycobacterium tuberculosis. J Immunol 2004, 172(June (11)):6913-6921.
26. Shi L., Jung Y.J., Tyagi S., Gennaro M.L., North R.J. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci U S A 2003, 100(January (1)):241-246.
27. Roche P.W., Triccas J.A., Avery D.T., Fifis T., Billman-Jacobe H., Britton W.J. Differential T-cell responses to mycobacterial secreted proteins distinquish between BCG vaccination and infection with Mycobacterium tuberculosis. J Infect Dis 1994, 170:1326-1330.
28. Huygen K., Content J., Olivier D., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996, 2:893-898.
29. Takatsu K., Kariyone A. The immunogenic peptide for Th1 development. Int Immunopharmacol 2003, 3(June (6)):783-800.
30. Romano M., Roupie V., Wang X.M., Denis O., Jurion F., Adnet P.Y., et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 2006, 118(July (3)):321-332.
31. Simeone R., Bottai D., Brosch R. ESX/type VII secretion systems and their role in host-pathogen interaction. Curr Opin Microbiol 2009, 12(February (1)):4-10.
32. Andersen P., Munk M.E., Pollock J.M., Doherty T.M. Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356(September (9235)):1099-1104.
33. Olsen A.W., van Pinxteren L.A.H., Okkels L.M., Rasmussen P.B., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infection Immunity 2001, 69(5):2773-2778.
34. Palendira U., Spratt J.M., Britton W.J., Triccas J.A. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 2005, 23(February (14)):1680-1685.
35. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28(April (20)):3571-3581.
36. Wiker H.G., MPB70 MPB83-major antigens of Mycobacterium bovis. Scand J Immunol 2009, 69(June (6)):492-499.
37. Xue T., Stavropoulos E., Yang M., Ragno S., Vordermeier M., Chambers M., et al. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun 2004, 72(November (11)):6324-6329.
38. Perera P.Y., Derrick S.C., Kolibab K., Momoi F., Yamamoto M., Morris S.L., et al. A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. Vaccine 2009, 27(March (15)):2121-2127.
39. Kolibab K., Parra M., Yang A.L., Perera L.P., Derrick S.C., Morris S.L. A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine 2009, 28(December (2)):317-322.
40. Delogu G., Li A., Repique C., Collins F., Morris S.L. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun 2002, 70(January (1)):292-302.
41. Derrick S.C., Yang A.L., Morris S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004, 23(December (6)):780-788.
42. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003, 171(August (3)):1602-1609.
43. Kamath A.T., Hanke T., Briscoe H., Britton W.J. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology 1999, 96(April (4)):511-516.
44. Kagina B.M., Abel B., Scriba T.J., Hughes E.J., Keyser A., Soares A., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am J Respir Crit Care Med 2010, (June 17).